MET x MET bispecific antibody REGN5093

{
  "id": "MLC-T-ONC-015114",
  "term": "MET x MET bispecific antibody REGN5093",
  "field": "Oncology and biomedicine",
  "definition": "A bispecific monoclonal antibody that targets two different epitopes of the human tumor-associated antigen (TAA) MET (c-MET; hepatocyte growth factor receptor; HGFR), with potential antineoplastic activity. Upon administration, MET x MET bispecific antibody REGN5093 targets and binds to two different, non-overlapping epitopes on MET expressed on the tumor cell surface, thereby forming unique REGN5093-MET complexes. The binding of REGN5093 to the MET epitopes and the unique complex formation causes MET internalization and degradation. This prevents MET-mediated signaling and inhibits growth of MET-driven tumor cells. MET, a receptor tyrosine kinase, is overexpressed on the cell surfaces of various solid tumor cell types where it is involved in epithelial-mesenchymal transition; it plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.",
  "synonyms": [
    "anti-c-Met bispecific antibody REGN5093",
    "METxMET antibody REGN5093",
    "METxMET bispecific antibody REGN5093"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/met-x-met-bispecific-antibody-regn5093/"
}